STOCK TITAN
  1. Home
  2. Sec-filings
  3. DNTH
  4. [EFFECT] Dianthus Therapeutics, Inc. /DE/ SEC Filing

[EFFECT] Dianthus Therapeutics, Inc. /DE/ SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: January 30, 2026 4:00 P.M.
Form: S-3
CIK: 0001690585
Company Name: Dianthus Therapeutics, Inc. /DE/
File Number: 333-293014

Source: View Original Filing on SEC EDGAR

Stock DNTH logo
Dianthus Therapeutics Inc

NASDAQ:DNTH

DNTH Rankings

#2072 Ranked by Market Cap
N/A Ranked by Dividends

DNTH Latest News

Jan 5, 2026
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
Dec 23, 2025
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
Nov 24, 2025
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
Nov 5, 2025
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Nov 4, 2025
Dianthus Therapeutics to Participate in Four Investor Conferences During November

DNTH Latest SEC Filings

Jan 28, 2026
[S-3] Dianthus Therapeutics, Inc. /DE/ Shelf Registration Statement
Jan 12, 2026
[8-K] Dianthus Therapeutics, Inc. /DE/ Reports Material Event
Nov 5, 2025
[10-Q] Dianthus Therapeutics, Inc. /DE/ Quarterly Earnings Report
Nov 5, 2025
[8-K] Dianthus Therapeutics, Inc. /DE/ Reports Material Event
Nov 3, 2025
[8-K] Dianthus Therapeutics, Inc. /DE/ Reports Material Event

DNTH Stock Data

2.31B
41.66M
7.86%
123%
17.33%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK